City
Epaper

Study discovers tool that help to improve liquid biopsy

By ANI | Published: July 04, 2023 8:48 AM

California [US], July 4 : A team of researchers led by Xianghong Jasmine Zhou, PhD, professor of Pathology and ...

Open in App

California [US], July 4 : A team of researchers led by Xianghong Jasmine Zhou, PhD, professor of Pathology and Laboratory Medicine at UCLA's David Geffen School of Medicine, has made significant progress in addressing one of the primary obstacles in cell-free DNA (cfDNA) testing, popularly known as liquid biopsy.

They discovered particular methylation patterns that are unique to each tissue, which might aid in identifying the precise tissue or organ involved with cfDNA abnormalities detected by testing, a major hurdle for accurate illness diagnosis and monitoring.

Cell-free DNA has great promise for disease identification and monitoring. However, reliably measuring tissue-derived cfDNA with existing methodologies has proven difficult, as has establishing the tissue origin of cfDNA fragments found in these tests.

In a new study, published in Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS), the team developed a comprehensive and high-resolution methylation atlas based on a vast dataset of 521 noncancerous tissue samples representing 29 major types of human tissues. They call the approach cfSort, and showed it successfully identified specific methylation patterns unique to each tissue at the fragment level and validated these findings using additional datasets.

Going further, the team illustrated the clinical applications of cfSort through two potential uses: aiding in disease diagnosis and monitoring treatment side effects. By estimating the tissue-derived cfDNA fraction using cfSort, they were able to assess and predict clinical outcomes in patients.

"We have shown that the cfSort outperformed the existing methods in terms of accuracy and detection limit: making more accurate tissue fraction estimation and distinguishing a lower level of tissue-derived cfDNA," said first author Shuo Li. "In addition, the cfSort demonstrated nearly perfect robustness toward the unseen local fluctuations of tissue compositions, indicating its wide applicability to diverse individuals."

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Clinical Chemistry and Laboratory MedicineXianghong jasmine zhouShuo LiUclaUcla jonsson comprehensive cancer centerDepartment of laboratory medicineHarbor ucla medical centerUcla school of dentistryUcla fielding school of public healthUcla healthArchives of pathology & laboratory medicineUcla samueli school of engineering
Open in App

Related Stories

InternationalUS Campus Protest: Many Injured as Violent Clashes Erupt at UCLA Between Pro-Palestinian and Pro-Israel Activists, Visuals Emerge

TechnologyRising temperatures are making it harder for birds to breed: Study

TechnologyPregnancy hormone repairs myelin damage in an MS mouse model: Study

Other SportsIndia finishes Asia Cup 2023 archery stage 3 with 7 medals

Other SportsAsia Cup archery stage 3: India end campaign with seven medals

Technology Realted Stories

TechnologyHumans not at risk of deadly chronic wasting disease: Study

TechnologyAWS, Microsoft Azure, Google Cloud now dominate 66 per cent of global Cloud spending

TechnologyWhy congenital heart disease remains a health concern in India

TechnologyDigital Competition Bill: Strengthen existing regulatory bodies like CCI, NCLAT, says Nasscom

TechnologyLack of self-sustained economic activity driving migration from some states: Zoho CEO